Metabolic healthtech company Biolinq has closed a $100 million Series C financing round to take its “autonomous intradermal glucose sensor” from development to commercial readiness. The company says the funding will support the final stages of regulatory review in the United States following the completion of a pivotal clinical trial.

San Diego-based Biolinq is focused on metabolic health monitoring through a novel biosensor platform, which uses an array of electrochemical microsensors that reside just beneath the skin’s surface to continuously measure analyte levels in the body. The intradermal placement of the sensor allows it to access a metabolically active area of the skin without needing to penetrate into deeper tissues.

The company’s first product is a wearable patch worn on the upper forearm that reads glucose levels in interstitial fluid, offering a minimally invasive alternative to other glucose monitoring techniques. A key feature of the device is a color-changing indicator light that provides immediate feedback about the wearer’s glucose status, with the aim of helping people with type 2 diabetes not on insulin to manage their condition.

Longevity watchers will be even more interested in where Biolinq takes its technology next. Built for multi-analyte sensing, the company’s platform is expected to expand into monitoring other biomarkers like lactate and ketones, which would broaden its appeal for health and wellness applications, and potentially extend its use into personalized medicine.

At present, Biolinq’s glucose sensor remains an investigational device and is not yet approved by the FDA or other regulatory bodies, but CEO Rich Yang expects that the new funding will support the product’s final steps towards commercialization.

Rich Yang is CEO of Biolinq

“This financing will bolster Biolinq’s commercial readiness efforts while we pursue regulatory approval for the first intradermal glucose sensor that incorporates activity and sleep information into a single wearable device,” he said “Our team has spent the last decade developing a biosensor platform designed to inspire healthier living by providing context around a person’s metabolic health.”

The new financing round, which builds on last year’s $58 million raise, was led by Alpha Wave Ventures with participation from existing investors including RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical, and Features Capital.

“With a highly differentiated product, Biolinq is well-positioned to expand the biosensor market,” said Alpha Wave’s Rick Gerson.